pLenti-EML4-ALK variant 1 Citations (2)

Originally described in: Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256. Epub 2018 Apr 12. PubMed Journal

---

Articles Citing pLenti-EML4-ALK variant 1

Articles
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu J. NPJ Precis Oncol. 2024 Mar 4;8(1):62. doi: 10.1038/s41698-024-00563-4. PubMed
Out-of-frame CBX3::ALK fusion drives ALK activation and therapy response. Hang JF, Cheng HY, Tsai YS, Lin SY, Song JH, Chung CH, Yang MH. Cell Rep Med. 2026 Apr 21;7(4):102697. doi: 10.1016/j.xcrm.2026.102697. Epub 2026 Mar 25. PubMed

If you have published an article using this material, please email us at to have your article added to this page.